Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
Conference Call Scheduled for August 14, 2025 4:30pm ET
Article content
VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market.
Article content
Following the release, management will host a conference call to review financial and operating results.
Article content
Conference Call Information:
Article content
To participate in the conference call, please use the dial-in information below:
Article content
Participant Listening: 1-877-407-9039 or 1-201-689-8470
or
https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6
– Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time.
Article content
The live audio webcast will be accessible here:
https://viavid.webcasts.com/starthere.jsp?ei=1726104&tp_key=1b6464373d A replay of the earnings call is available after the conference call has ended.
Replay Dial-In: 1-844-512-2921 or 1-412-317-6671 Access ID: 13754595
Replay webcast: https://viavid.webcasts.com/starthere.jsp?ei=1726104&tp_key=1b6464373d About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options.
Article content
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.]
Article content
Forward-looking Statements
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's [ Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov. ] These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
23 minutes ago
- Globe and Mail
Levi & Korsinsky Notifies 3D Systems Corporation (DDD) Shareholders of Class Action Lawsuit and August 12, 2025 Deadline
New York, New York--(Newsfile Corp. - August 4, 2025) - If you suffered a loss on your 3D Systems Corporation (NYSE: DDD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against 3D Systems Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between August 13, 2024 and May 12, 2025. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (ii) in addition, the updated milestone criteria in the partnership with United Therapeutics Corporation would negatively impact the Company's regenerative medicine program revenue; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in 3D Systems Corporation stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CTV News
23 minutes ago
- CTV News
Two of Canada's most senior ministers head to Mexico to talk discuss trade
The flags of Mexico and Canada fly near the Ambassador Bridge, Monday, Feb. 3, 2025, in Detroit. (AP Photo/Paul Sancya) Two of Canada's most senior cabinet ministers will be in Mexico City this week holding bilateral meetings with government officials and the Mexican president, as Canada looks to improve its trading partnerships outside the United States. Senior government officials confirmed to CTV News that the meeting, which will involve Finance Minister Francois-Philippe Champagne and Foreign Affairs Minister Anita Anand, will take place Tuesday and Wednesday. The talks are expected to cover trade and the larger relationship between the two countries. That relationship suffered in the past year, when Ontario Premier Doug Ford called on Canada to seek a unilateral trade deal with the United States – without Mexico – and accused the country of undercutting North American manufacturers. Canadian business leaders say the upcoming talks show an effort to strengthen ties at a time when both countries are facing volatility from the United States. 'When we talk to Mexico, when we talk to their embassies in Canada, they are very eager to reset the relationship,' Catherine Fortin-LeFaivre, senior vice-president of International Policy and Global Partnerships at the Canadian Chamber of Commerce, said Sunday. While Canada faces new blanket 35 per cent tariffs on Canadian goods that aren't covered under the Canada-United States-Mexico Agreement, Mexico received a 90-day extension to continue trade talks with the U.S. before it sees blanket tariffs increase from 25 per cent to 35 per cent. Last month, Prime Minister Mark Carney and Mexican President Claudia Sheinbaum spoke over the phone, with the two leaders agreeing to improve trade collaboration between the two nations. Carlo Dade, director of international policy at the University of Calgary's School of Public Police, said Canada having open dialogue and strong ties with Mexico is 'a good sign.' 'If we weren't talking to Mexico, there would be reason to be concerned and worried,' Dade told CTV News. He added that Canada hasn't taken advantage of being in close proximity to a country like Mexico that has a higher per-capita GDP than China. 'The infrastructure is there, we have CPKC - Canada-Pacific Kansas City Railroad - so there's (an) integrated North American railroad,' Dade said. 'We have a trade agreement, we have decades of strong, strong, political and economic relations – the only missing factor has been a willingness of Canadian business to seize the opportunities. Mexico has been marked as a priority market to expand trade with by Export Development Canada. While it is already Canada's third-largest trading partner, with nearly $56 billion dollars in two-way merchandise crossing the border in 2024, it represented just over one per cent of Canadian exports that year. Fortin-LeFaivre says those relations will be crucial, particularly if the United States looks to move from a trilateral free trade agreement to two bilateral deals. 'It will be imperative that if that is happening that we have a very strong connection with Mexico directly, without the U.S. being there,' she said. Friday, Carney reiterated Canada's commitment to the CUSMA agreement while condemning Trump's recent tariff increase.
CBC
24 minutes ago
- CBC
Finance and foreign affairs ministers travel to Mexico to strengthen trade partnership
Finance Minister François-Philippe Champagne confirmed Monday that he and Foreign Affairs Minister Anita Anand will be travelling to Mexico City in an effort to strengthen Canada's trade ties with Mexico. The ministers are expected to return to Canada on Thursday, according to two senior Canadian government sources.
